Associated Papers
Histiocytic Sarcoma Arising From Pediatric Rosai Dorfman Disease: Two Novel Cases and Literature Review.
Sirotnikov S et al.
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 2026
Effects of F53 hotspot mutations on the molecular dynamics of MEK1 protein and the binding of its FDA-approved inhibitors.
Vural BE et al.
International Journal of Biological Macromolecules, 2025
Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis.
Wang CJ et al.
Archives of Pathology & Laboratory Medicine, 2025
Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations.
Pai P et al.
Molecular Biotechnology, 2025
BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes.
Lang M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
MAP2K1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations.
Alomari AK et al.
Journal of Cutaneous Pathology, 2023
Evolutionary history of MEK1 illuminates the nature of deleterious mutations.
Andrianova EP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M et al.
European Journal of Cancer (oxford, England : 1990), 2023
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S et al.
Molecular Cancer Therapeutics, 2023
Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients.
de Bitter TJJ et al.
Npj Precision Oncology, 2022
Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.
Yang Y et al.
Journal of Cancer Research and Clinical Oncology, 2022
Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma.
Xiang C et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
[Classic hairy cell leukemia with MAP2K1 mutation: a case report].
Wei C et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2022
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.
Maitre E et al.
Cancers, 2022
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.
Chihara D et al.
Blood Advances, 2021
Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
Massoth LR et al.
The Oncologist, 2021
MAP2K1-Mutated Melanocytic Neoplasms With a SPARK-Like Morphology.
Donati M et al.
The American Journal of Dermatopathology, 2021
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.
Hanrahan AJ et al.
Cancer Research, 2020
A mosaic variant in MAP2K1 is associated with giant naevus spilus-type congenital melanocytic naevus and melanoma development.
Muthiah S et al.
The British Journal of Dermatology, 2020
Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
Hayase T et al.
International Journal of Hematology, 2020
How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study.
Liu Y et al.
Journal of Biomolecular Structure & Dynamics, 2020
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C et al.
Haematologica, 2020
The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
Costigan DC et al.
Genes, Chromosomes & Cancer, 2020
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.
Maitre E et al.
Oncotarget, 2018
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
Andritsos LA et al.
Leukemia & Lymphoma, 2018
Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.
Jallades L et al.
Haematologica, 2017
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.
Waterfall JJ et al.
Nature Genetics, 2014
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Emery CM et al.
Proceedings of the National Academy of Sciences of the United States of America, 2009